Shkreli's Pricing Strategy May Be Curbed by FDA

With a small regulatory change, the U.S. Food and Drug Administration may have just stopped the next Martin Shkreli.

The agency said Friday that it will prioritize review of new applications for generic drugs that would compete with treatments made by only one company. That could help make it less profitable for somebody like Shkreli, who was until last year the chief executive officer of Turing Pharmaceuticals AG, from buying an old, patent-expired drug with no competition and jacking up the price.